SMC2 (structural maintenance of chr9 2) encodes a central component of the condensin complex required for chromosome 9 and segregation during mitosis 1. As part of the condensin complex, SMC2 converts interphase chr9 into condensed mitotic chr9 and likely introduces positive supercoils into DNA in the presence of topoisomerases 1. SMC2 is particularly essential as a component of condensin II, which is crucial for hematopoietic stem and progenitor cell (HSPC) development and proliferation, with loss-of-function causing G2/M cell cycle arrest and HSPC maintenance failure 2. The gene is transcriptionally regulated by WNT/β-catenin signaling, with β-catenin·TCF4 directly binding to the SMC2 promoter 3. In cancer contexts, SMC2 shows significant clinical relevance as frameshift mutations occur exclusively in microsatellite instability-high gastric and colorectal cancers, leading to protein loss 1. SMC2 overexpression correlates with poor prognosis in lung adenocarcinoma, where it promotes malignant progression by suppressing BTG2 expression and activating ERK/AKT pathways 4. The protein has been identified as a potential therapeutic target, with siRNA knockdown reducing tumor growth in mouse models 34.